Penserra Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Penserra Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-279	Closed	-$59K	–	1089
2025 Q4	$59K	Buy	+279	New	+$57.6K	﹤0.01%	759
2025 Q2	–	Sell	-2,695	Closed	-$420K	–	1028
2025 Q1	$420K	Buy	+2,695	New	+$385K	0.01%	623
2024 Q2	–	Sell	-19,412	Closed	-$2.93M	–	1255
2024 Q1	$2.93M	Buy	19,412 +15,964	+463%	+$2.28M	0.04%	304
2023 Q4	$434K	Buy	+3,448	New	+$344K	0.01%	558

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Penserra Capital Management's ASND Position: Q1 2026 in Review

Penserra Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 279 shares — an estimated $59K sold.

Penserra Capital Management first reported a position in ASND in Q4 2023 and held it in 4 quarters. The position peaked at $2.93M in Q1 2024. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Penserra Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Penserra Capital Management sold 279 Ascendis Pharma A/S shares in Q1 2026, an estimated $59K.
Penserra Capital Management first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 4 quarters.
Penserra Capital Management's Ascendis Pharma A/S position peaked at $2.93M in Q1 2024.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.